A feasibility study: Improving management of comorbidity in patients with colorectal cancer

Not Applicable

• Conditions: colorectal cancer; comorbidity; Cancer - Bowel - Back passage (rectum) or large bowel (colon)

• Registration Number: ACTRN12615001312538
• Lead Sponsor: Dr Christopher Jackson

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-12-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

patients with newly diagnosed colorectal adenocarcinoma who have undergone or who are planned to undergo major resection
OR
Metastatic relapse of colorectal adenocarcinoma, as judged by histological confirmation of relapse or as confirmed by a specialist multi-disciplinary team meeting (MDTM)
OR
Undifferentiated carcinoma (grade 4) with clinical features consistent with colorectal cancer (and confirmed by a MDTM) will be permitted.

Exclusion Criteria

Histological or cytological diagnosis of cancer type other than adenocarcinoma;
Adenocarcinoma of colon or rectum with polypectomy or local excision as only treatment;
Treatment acuity such that intervention not able to be administered without potentially compromising patient outcome (e.g acute or sub-acute bowel obstruction, incipient perforation, major GI haemorrhage);
Unable to give informed consent;
Not able to comply with follow up;
Locally recurrent rectal cancer without metastatic relapse;
Life expectancy less than three months from diagnosis.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of patients with colorectal adenocarcinoma who are approached who consent to enter.<br><br>This outcome will be assessed by use of a screening log, this will capture all those who are approached and whether they consented to proceed.[At one year after enrolment of first eligible patient];Proportion of patients who consent to enter whom complete screening criterial and fulfil criteria to proceed to CMA<br><br>This outcome will be assessed by use of a screening log, whether or not a subject proceeds to CMA will be captured as part of the screening log.[one year from enrolment of first eligible patient];Narrative of comorbid conditions identified at CMA[one year from enrolment of first eligible patient]

Secondary Outcome Measures

Name	Time	Method
Discrepancy between medications identified at admission and those held by GP and at pharmacy. <br><br>This outcome will be assessed by identifying the medications noted on the study screening form, and by telephone contact with GP. [one year from enrolment of first eligible patient];Completion rate of QOL <br><br>Whether a QOL is completed will be captured on the subject screening log, the study coordinator will note the date the QOL was completed, if it was not completed a note explaining why e.g subject refused.[one year from enrolment of first eligible patient];Narrative feedback from participants (including physicians)[one year from enrolment of first eligible patient]